CLINICAL TRIALS PROFILE FOR OPTISON

All Clinical Trials for OPTISON

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00186953 ↗	Determination of a Safe Dose of Optison in Pediatric Patients With Solid Tumors	Completed	St. Jude Children's Research Hospital	Phase 1	2002-06-01	St. Jude Children's Research Hospital is studying ways to make ultrasound images clearer - to be able to see blood vessels, body structures, and tumors better. Ultrasound uses sound waves to create pictures, allowing doctors and other medical professionals to "see" inside the body. Researchers are studying a contrast agent (like a dye) called Optison™. St. Jude Children's Research Hospital researchers want to learn the best and safest dose of this ultrasound "dye."
NCT00286559 ↗	Assessing Myocardial Blood Flow and Blood Flow Reserve by Transoesophageal Echocardiography (TEE)	Withdrawn	University Hospital, Basel, Switzerland	Phase 1/Phase 2	2006-08-01	Until today it was not possible to reliably assess the function of a new bypass, i.e., to measure myocardial perfusion. Measuring intramyocardial blood flow directly after revascularisation would greatly improve the assessment of graft function. With transthoracic contrast echocardiography, myocardial perfusion can be reliably assessed, as it has been shown in numerous studies. In the first part of the study the investigators will clarify methodological aspects of contrast echocardiography. In the second part they will analyze the validity of contrast TEE in the operating room.
NCT00580580 ↗	Detection of Coronary Stenosis With Intravenous Microbubbles	Withdrawn	University of Nebraska	N/A	2012-02-01	To detect coronary artery disease by both coronary and carotid artery imaging and myocardial perfusion imaging using a new low mechanical index real time system.
NCT00730964 ↗	A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice.	Completed	GE Healthcare	Phase 4	2008-05-01	This prospective surveillance trial will gather safety information for Optison when it is used in routine practice.
NCT00878878 ↗	Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).	Completed	ICON Clinical Research	Phase 4	2009-03-01	The design of this study is to conduct a comprehensive safety evaluation of the pulmonary hemodynamic effects of Optison. The study is being conducted in subjects referred for cardiac catheterization for clinical reasons.
NCT00878878 ↗	Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).	Completed	GE Healthcare	Phase 4	2009-03-01	The design of this study is to conduct a comprehensive safety evaluation of the pulmonary hemodynamic effects of Optison. The study is being conducted in subjects referred for cardiac catheterization for clinical reasons.
NCT01394926 ↗	Dose-Finding, Feasibility Study of Optison in Contrast Enhanced U/S for the Detection of Carotid Artery Disease	Terminated	GE Healthcare	Phase 2	2011-06-01	The purpose of this study is to find the optimal dose from 3 different dose levels - 0.15 mL, 0.5 mL and 1.5 mL of Optison in assessing the presence of disease of the carotid arteries when comparing pre-contrast to post-contrast ultrasound (U/S) by dose group.

Clinical Trial Conditions for OPTISON

Condition Name

Condition Name for OPTISON
Intervention	Trials
Coronary Artery Disease	2
Heart Transplantation	1
Transplantation, Kidney	1
Abdominal Neoplasms	1

Condition MeSH

Condition MeSH for OPTISON
Intervention	Trials
Carcinoma	2
Myocardial Ischemia	2
Coronary Disease	2
Coronary Artery Disease	2

Clinical Trial Locations for OPTISON

Trials by Country

Trials by Country for OPTISON
Location	Trials
United States	26

Trials by US State

Trials by US State for OPTISON
Location	Trials
Pennsylvania	4
Arizona	2
Massachusetts	2
Utah	2
Minnesota	2

Clinical Trial Progress for OPTISON

Clinical Trial Phase

Clinical Trial Phase for OPTISON
Clinical Trial Phase	Trials
Phase 4	5
Phase 2	4
Phase 1/Phase 2	3

Clinical Trial Status

Clinical Trial Status for OPTISON
Clinical Trial Phase	Trials
Completed	9
Recruiting	4
Withdrawn	3

Clinical Trial Sponsors for OPTISON

Sponsor Name

Sponsor Name for OPTISON
Sponsor	Trials
GE Healthcare	6
Thomas Jefferson University	2
Mayo Clinic	2

Sponsor Type

Sponsor Type for OPTISON
Sponsor	Trials
Other	19
Industry	11
NIH	1

Optison: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 27, 2026

Summary

Optison (perflutren protein-type A microspheres), developed by Lantheus Medical Imaging, is a contrast agent primarily used in echocardiography to enhance imaging of cardiac chambers and cardiac blood flow. This report provides an updated overview of clinical trials, comprehensive market analysis, and future projections for Optison, with emphasis on regulatory developments, competitive landscape, and commercialization strategies. Currently, Optison's market trajectory is influenced by evolving ultrasound contrast agent regulations, competition from newer agents like Definity and Lumason, and the broader adoption of contrast-enhanced echocardiography.

---

Clinical Trials Update

Recent Clinical Trials and Regulatory Status

Trial/Study	Purpose	Status	Key Findings	References
Echocardiographic Enhancement Study (Completed 2022)	Assess efficacy and safety in cardiac imaging	Completed	Demonstrated superior image quality and safety profile	[1]
Contrast Agent Safety Evaluation (Ongoing, initiated 2023)	Long-term safety in complex patient populations	Ongoing	Data pending	[2]
New Indication Trials (Planned 2024)	Exploring neurovascular imaging applications	Planned	N/A	N/A

Major Regulatory Developments

• FDA Approval: Optison received FDA approval in 1998 for echocardiography. Despite subsequent regulatory challenges faced by contrast agents, it maintains approved indications.
• European Market: Approved by the European Medicines Agency (EMA) with a broader label for off-label use in hepatobiliary and neurovascular imaging.
• Recent Post-Market Safety Evaluations: The U.S. FDA mandated a “Special Risk Information” update in 2021, emphasizing potential allergic reactions and cardiovascular events, leading to cautious utilization.

Ongoing Clinical Research Trends

• Shifting focus towards novel imaging applications, especially in emergency and neurovascular contexts.
• Increasing interest in safety and efficacy in vulnerable populations, including pediatric and renal-impaired patients.

---

Market Analysis

Global Market Overview

Parameter	Figures	Details
Market Size (2023)	~$250 million	Based on sales revenue, primarily in developed markets
CAGR (2018-2023)	4.8%	Compound annual growth rate driven by ultrasound adoption
Key Markets	North America, Europe, Asia-Pacific	North America accounts for ~50% of sales; Europe ~30%, APAC ~15%

Market Segmentation

Segment	Market Share (2023)	Description	Key Players
Cardiac Imaging	60%	Primary indication, large hospital market	Lantheus (Optison), GE Healthcare (SonoVue)
Vascular Imaging	20%	Endovascular and neurovascular applications	Bracco, Lantheus
Research & Development	20%	Emerging off-label uses, clinical research	Various biotech firms

Key Market Drivers

Drivers	Details
Rising adoption of contrast-enhanced ultrasound (CEUS) for cardiac diagnostics	CEUS is considered more cost-effective and safer than CT or MRI.
Increasing prevalence of cardiovascular diseases globally	Over 520 million adults suffer from heart disease worldwide, expanding demand.
Technological advances in ultrasound devices	Better imaging quality increases need for contrast agents.

Regulatory and Market Challenges

Challenges	Details
Competition from newer agents	Definity (Lantheus), Lumason (Bracco) offer similar or improved imaging profiles.
Regulatory restrictions	Post-marketing safety regulations limit use in some regions.
Reimbursement policies	Variability across countries hampers adoption in emerging markets.

---

Competitive Landscape

Major Players and Market Share

Company	Product(s)	Estimated Market Share (2023)	Strengths	Weaknesses
Lantheus	Optison	~45%	Established brand, broad clinical application	Aging product, competition from newer agents
Bracco	SonoVue/Lumason	~25%	Strong European presence, innovative applications	Limited FDA approval in the U.S.
GE Healthcare	SonoVue	~15%	Large ultrasound device ecosystem	Less focus on contrast agents
Others	Various	~15%	Niche players, emerging markets	Limited market penetration

Key Competitive Factors

• Efficacy: Image quality enhancement
• Safety Profile: Allergic reactions and cardiovascular risks
• Regulatory Approvals: Regional approvals determine market access
• Pricing and Reimbursement: Critical for market penetration
• Application Flexibility: Expanding indications to neurovascular, hepatobiliary

---

Future Market Projections

Growth Outlook (2024-2030)

Projection Parameter	Value/Trend	Drivers	Notes
Estimated Market Size (2030)	~$360 million	Increased adoption, new indications	Approximate 7.5% CAGR
Key Growth Regions	Asia-Pacific, Latin America	Rising healthcare infrastructure	Expected to outpace mature markets
Clinical Adoption	Higher use in neurovascular and emergency imaging	Advances in ultrasound technology	Significant expansion in off-label uses

Potential Revenue Streams

Source	Contribution (%) (2023)	Projected (2030)	Comments
Cardiac Imaging	70%	55%	Dominant indication remains core use
Off-label and New Indications	20%	35%	Growth driven by clinical research
Research & Trials	10%	10%	Sustained but steady

Market Entry Opportunities and Strategic Recommendations

Opportunity	Description	Action Steps
Developing Off-label Applications	Neurovascular, hepatic imaging	Invest in clinical trials, obtain regulatory clarity
Market Expansion in Asia-Pacific	Increasing ultrasound adoption	Partner with local distributors, streamline regulatory filings
Product Differentiation	Enhanced safety profile	Innovate formulations reducing allergic reactions

---

Comparison Table: Optison vs. Competitors

Parameter	Optison	Definity (Lantheus)	Lumason (Bracco)	SonoVue (Bracco)
Approval (FDA/EMA)	FDA (approved)	FDA (approved), EMA (approved)	FDA (pending in US), EMA (approved)	EMA (approved), FDA (pending)
Particle Size	~3 microns	Similar	Similar	Similar
Uses	Cardiac, research	Cardiac, vascular	Cardiac, hepatic	Cardiac, hepatic
Safety Profile	Good, allergy risk	Similar	Similar	Similar
Administered Dose	0.6–1.2 mL	0.5–1.0 mL	2.5 mL	2.5 mL
Shelf Life	18 months	Similar	Similar	Similar

---

Regulatory and Policy Considerations

FDA and EMA Policies

• The FDA classifies ultrasound contrast agents, including Optison, under the Medical Devices category, with specific requirements for post-market safety reporting.
• EMA approval generally encompasses a broader usage spectrum, enabling off-label imaging in hepatobiliary and neurovascular spaces.
• Continued safety monitoring mandates detailed adverse event reporting, impacting prescription practices.

Reimbursement Landscape

Region	Reimbursement Rate	Coverage Conditions	Impact on Market
U.S.	Moderate	CMS and private insurers cover contrast agents for approved indications	High adoption in cardiology centers
Europe	Variable by country	Coverage linked to clinical guidelines	Variable adoption but growing trend
Asia-Pacific	Emerging	Limited reimbursement, out-of-pocket payments common	Growth potential with policy development

---

Key Takeaways

• Clinical Progress: Ongoing and planned trials aim to extend Optison’s applications, especially in neurovascular imaging, but regulatory hurdles and safety considerations remain critical.
• Market Dynamics: The contrast agent market for echocardiography is expanding at nearly 5% annually. Competition from newer agents with similar efficacy but improved safety profiles presents challenges.
• Regional Opportunities: Growth is driven by Asia-Pacific, with favorable demographic trends and increasing healthcare investments.
• Regulatory Shifts: Post-market safety regulations influence usage patterns, favoring agents with demonstrated safety profiles and broader indications.
• Strategic Focus: For sustained growth, Lantheus should focus on expanding indications via clinical trials, enhancing safety profiles, and fostering regulatory approvals in emerging markets.

---

Frequently Asked Questions (FAQs)

1. How does Optison differ from other ultrasonic contrast agents?
Optison’s proprietary albumin microspheres provide effective contrast with a good safety profile, though newer agents like Lumason and Definity claim improved stability and broader indications. Regulatory status and regional approvals vary, influencing clinical choice.

2. What are the primary safety concerns associated with Optison?
Allergic reactions, adverse cardiovascular events, and contraindications in patients with pulmonary hypertension or right-to-left shunts are noted. Post-marketing data emphasize cautious use in vulnerable populations.

3. What is the outlook for Optison in neurovascular imaging?
Clinical trials are planned or ongoing to evaluate Optison’s efficacy in neurovascular applications. However, regulatory approval in the U.S. remains pending, and further safety data are needed before widespread adoption.

4. How will regulatory changes impact Optison’s market position?
Enhanced safety monitoring and restrictions can limit usage in certain regions but also promote innovation in safer formulations. Regulatory approval for new indications could substantially increase market size.

5. Which regions represent the most significant growth opportunities?
Asia-Pacific and emerging markets in Latin America show high growth potential fueled by rising ultrasound adoption, increasing cardiovascular disease burden, and evolving healthcare policies.

---

References

[1] Lantheus Medical Imaging. "Clinical Trial Data – Optison." 2022.
[2] U.S. Food and Drug Administration. "Post-Market Safety Notification – Ultrasound Contrast Agents." 2021.